Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 38.8 CNY -0.18% Market Closed
Market Cap: ¥8.9B

P/OCF

17.9
Current
17%
Cheaper
vs 3-y average of 21.5

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
17.9
=
Market Cap
¥8.8B
/
Operating Cash Flow
¥491m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
17.9
=
Market Cap
¥8.8B
/
Operating Cash Flow
¥491m

Valuation Scenarios

Shanghai Haohai Biological Technology Co Ltd is trading below its 3-year average

If P/OCF returns to its 3-Year Average (21.5), the stock would be worth ¥46.74 (20% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+126%
Average Upside
66%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 17.9 ¥38.8
0%
3-Year Average 21.5 ¥46.74
+20%
5-Year Average 40.3 ¥87.57
+126%
Industry Average 38.2 ¥82.95
+114%
Country Average 18.3 ¥39.64
+2%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
8.8B CNY 17.9 35
FR
Pharnext SCA
OTC:PNEXF
6T USD -211 714.7 -160 127.7
US
Abbvie Inc
NYSE:ABBV
354.5B USD 18.7 85
US
Amgen Inc
NASDAQ:AMGN
186.5B USD 18.9 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
164.9B USD 16.6 19.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.2B USD 30.6 28.1
US
Epizyme Inc
F:EPE
94.1B EUR -531.3 -533.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD 15.8 17.5
NL
argenx SE
XBRU:ARGX
42B EUR 122.6 38.3
US
Seagen Inc
F:SGT
39.3B EUR -85.8 -61.8
AU
CSL Ltd
ASX:CSL
62.3B AUD 11.8 30.4
P/E Multiple
Earnings Growth PEG
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average P/E: 34.8
35
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
85
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.5
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
14%
1.3
NL
argenx SE
XBRU:ARGX
38.3
30%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
30.4
9%
3.4

Market Distribution

In line with most companies in China
Percentile
49th
Based on 6 232 companies
49th percentile
17.9
Low
0.2 — 9.8
Typical Range
9.8 — 36.5
High
36.5 —
Distribution Statistics
China
Min 0.2
30th Percentile 9.8
Median 18.3
70th Percentile 36.5
Max 266 666.7

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
8.9B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 30%
Intrinsic Value
Price ¥38.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett